Is fecal elastase low in cystic fibrosis?

Yes, Fecal Elastase is Low in Cystic Fibrosis

Cystic fibrosis is a high-risk condition for exocrine pancreatic insufficiency (EPI), and the vast majority of patients with CF will have low fecal elastase levels, typically <100 μg/g of stool, indicating severe pancreatic insufficiency 1.

Understanding the Relationship

Cystic fibrosis causes EPI through loss of pancreatic parenchyma and reduced pancreatic enzyme synthesis and secretion, along with reduced bicarbonate delivery 1. This makes CF one of the most predictable causes of low fecal elastase:

• CF is explicitly listed as a high-risk condition where EPI should be suspected and tested 1
• Fecal elastase <100 μg/g provides good evidence of EPI, while levels of 100-200 μg/g are indeterminate 1
• The test should be performed on semi-solid or solid stool specimens 1

Prevalence and Timing in CF

The pancreatic insufficiency in CF develops early and progressively:

• In patients with class 1 or 2 CFTR mutations, all infants had fecal elastase <100 μg/g by 6 months of age and were universally pancreatic insufficient by 12 months 2
• Approximately 80-90% of CF patients are pancreatic insufficient at diagnosis or develop it early in life 3, 4
• Among CF patients with severe to moderate EPI, fecal elastase sensitivity is 100% when using the <200 μg/g cutoff 5

Genotype Correlation

There is a strong association between CFTR mutation type and fecal elastase levels:

• 100% of homozygous ΔF508 patients showed fecal elastase <100 μg/g, indicating pancreatic insufficiency 4
• Heterozygous patients and those without ΔF508 mutations had less frequent severe pancreatic insufficiency 4

Important Clinical Caveats

Testing Considerations

• Fecal elastase testing can be performed while patients are on pancreatic enzyme replacement therapy (PERT), making it practical for ongoing monitoring 1
• The test is highly specific for severe EPI (elastase <100 μg/g) but less reliable for mild forms of pancreatic insufficiency 5

Era of CFTR Modulators

Recent evidence suggests the landscape may be evolving with newer therapies:

• Most pediatric CF patients on elexacaftor-tezacaftor-ivacaftor (ETI) therapy show no significant improvement in fecal elastase levels despite improvements in other parameters 6
• Patients who start CFTR modulators in adulthood are unlikely to experience reduction in PERT requirements and should continue close monitoring 7
• A small subset of patients may show improvement in pancreatic function with modulators, particularly if started very early, warranting repeat testing with clinical status changes 8

Variability in Infancy

• Infants with initial fecal elastase values of 50-200 μg/g show variability during the first year and should have repeat testing at 1 year of age to avoid unnecessary PERT 9
• However, infants with initial values <50 μg/g uniformly remain pancreatic insufficient 9

Practical Algorithm

At CF diagnosis:

• Obtain fecal elastase on semi-solid or solid stool
• Values <100 μg/g: Severe EPI confirmed → Start PERT
• Values 100-200 μg/g: Indeterminate → Start PERT and retest
• Values >200 μg/g: Pancreatic sufficient → Monitor, as insufficiency can develop over time

During follow-up:

• Patients on CFTR modulators should have repeat fecal elastase testing, especially with clinical status changes 8
• Infants with borderline values (50-200 μg/g) require retesting at 1 year 9
• Most patients will require lifelong PERT regardless of modulator therapy 6, 7